Will Stocks Rebound After Fed Decision? | Midas Letter RAW ft $TRYP biopub.co


Midas Letter

Midas Letter

Will Stocks Rebound After Fed Decision? | Midas Letter RAW ft $TRYP biopub.co


Investors and traders are still digesting Jerome Powell’s remarks regarding the latest Federal Reserve FOMC news conference making. However, thanks to Microsoft Corporation (NASDAQ:MSFT), Tesla Inc (NASDAQ:TSLA), and Apple Inc (NASDAQ:AAPL) beating earnings this week, investors are torn between upbeat financials and the prospect of interest rate rises.

It has been one of the worst ever January’s for investors. Although today is looking more positive, the S&P 500 (INDEXSP: .INX) and NASDAQ-100 (INDEXNASDAQ:NDX) are still on track for another weekly decline.

Will the current bounce/rebound keep going into next week or beyond? Or will the bear market continue until the Fed is forced to change its direction? Watch to find out.

We have two exclusive interviews on deck this week:

BioPub.co Founder Dr. Mark Swaim
BioPub is a small-cap biotech investing website, where PhDs and MDs deliberate daily about biotech, medical and investment questions. The website’s goal is to be the secret weapon and unfair advantage of every subscriber. The website founder highlights three little-known biotech companies he foresees will succeed, and investors may find value. AcuRx Pharmaceuticals (NASDAQ:ACXP), Medicenna Therapeutics Corp (NASDAQ:MDNA), NervGen Pharma Corp (CVE:NGEN).

TRYP Therapeutics is developing psilocybin-based compounds to treat diseases with unmet medical needs through accelerated regulatory pathways. The company is currently developing psilocybin-based treatments for chronic pain indications and eating disorders. They have recently announced upcoming Phase 2a clinical trials with the University of Michigan and Florida to evaluate its drug products for fibromyalgia and overeating disorders.


00:00 – Midas Letter RAW
00:50 – Coming Up
01:40 – Audience Questions
01:41 – What are we bullish on?
02:32 – When to expect rate hikes?
04:52 – Buying calls on ETFs
08:18 – Finance career tips & advise
10:14 – NuRAN Wireless towers
10:43 – Buying opportunities for long-term focused investors?
12:42 – Biopub.co interview
29:19 – Fed FOMC rate decision
31:38 – Market reaction to Powell remark
35:28 – Super bubble (around 8mins)
36:28 – 10-year rate
39:19 – NASDAQ chart
40:28 – Bill Ackman $NFLX buy
40:43 – Market prognosis
42:15 – Crypto
44:49 – TRYP Therapeutics CEO interview
56:27 – $TRYP Chart
56:41 – Cannabis industry vs psychedelics industry
57:15 – Psychedelics developmental phase
57:49 – Gold sell-off
01:00:11 – Voxtur Analytics Corp $VXTR $VXTRF
01:02:37 – NuRAN Wireless $NUR $NRRWF
01:03:25 – Graphene Manufacturing Group $GMG $GMGMF
01:03:54 – US Copper $USCU $USCUF
01:04:49 – Real Luck Group $LUCK $LUKEF

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *